POS-832 DAPAGLIFLOZIN IN IgA NEPHROPATHY: FINDINGS FROM THE DAPA-CKD TRIAL

• H. Lambers Heerspink,
• R.D. Toto,
• N. Jongs,
• P. Vart,
• G.M. Chertow,
• F.F. Hou,
• J.J.V. McMurray,
• R. Pecoits-Filho,
• R. Correa-Rotter,
• P. Rossing,
• C.D. Sjöström,
• B.V. Stefánsson,
• K. Umanath,
• A.M. Langkilde,
• D.C. Wheeler

Affiliations

H. Lambers Heerspink

University of Groningen University Medical Center Groningen, Department Clinical Pharmacy and Pharmacology, Groningen, Netherlands

R.D. Toto

UT Southwestern Medical Center, Department of Internal Medicine, Dallas, United States

N. Jongs

University of Groningen University Medical Center Groningen, Department Clinical Pharmacy and Pharmacology, Groningen, Netherlands

P. Vart

University of Groningen University Medical Center Groningen, Department Clinical Pharmacy and Pharmacology, Groningen, Netherlands

G.M. Chertow

Stanford University School of Medicine, Departments of Medicine and Epidemiology and Population Health, Stanford, United States

F.F. Hou

Nanfang Hospital- Southern Medical University- National Clinical Research Center for Kidney Disease, Division of Nephrology, Guangzhou, China

J.J.V. McMurray

University of Glasgow, Institute of Cardiovascular and Medical Sciences, Glasgow, United Kingdom

R. Pecoits-Filho

Pontificia Universidade Catolica do Parana, School of Medicine, Curitiba, Brazil

R. Correa-Rotter

National Medical Science and Nutrition Institute Salvador Zubirán, Department of Nephrology and Mineral Metabolism, Mexico City, Mexico

P. Rossing

University of Copenhagen, Department of Clinical Medicine, Copenhagen, Denmark

C.D. Sjöström

AstraZeneca, Late-stage Development Cardiovascular Renal and Metabolism Biopharmaceuticals R&D, Gothenburg, Sweden

B.V. Stefánsson

AstraZeneca, Late-stage Development Cardiovascular Renal and Metabolism Biopharmaceuticals R&D, Gothenburg, Sweden

K. Umanath

Henry Ford Hospital- Wayne State University, Division of Nephrology and Hypertension, Detroit, United States

A.M. Langkilde

AstraZeneca, Late-stage Development Cardiovascular Renal and Metabolism Biopharmaceuticals R&D, Gothenburg, Sweden

D.C. Wheeler

University College London, Department of Renal Medicine, London, United Kingdom